12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alimta Pemetrexed: Phase III data

The open-label Phase III POINTBREAK study in 939 patients with previously untreated stage IIIb/IV non-squamous NSCLC showed that Alimta plus Avastin bevacizumab as maintenance therapy missed the primary endpoint of improving median OS vs. Avastin as maintenance therapy (12.6 vs. 13.4 months, p=0.949). However, the Alimta arm met the secondary endpoint of improving median PFS vs. Avastin alone (6.0 vs. 5.6 months, p=0.012)....

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >